Theralase TechnologiesTSXV:TLT -5.45%39 Median PS Value is C$0.15 as of Jul. 06, 2026, which is 100% below its 10-year median of 1.92. GuruFocus rates TSXV:TLT with a GF Score™ of 39/100 and a GF Value™ of C$0.18 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 337 Medical Devices & Instruments companies, Theralase Technologies ranks worse than 92.58% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Theralase Technologies's Median PS Value or its related term are showing as below:
TSXV:TLT'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.13 Med: 1.92 Max: 5.75
Current: 1.73
During the past 13 years, the highest Price to Median PS Value of Theralase Technologies was 5.75. The lowest was 1.13. And the median was 1.92.
TSXV:TLT's Price-to-Median-PS-Value is ranked worse than 92.58% of 337
companies
in the Medical Devices & Instruments industry
Industry Median: 0.72
vs TSXV:TLT: 1.73
Theralase Technologies (TSXV:TLT) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Theralase Technologies's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.26
/
0.15
=
1.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies Median PS Value Related Terms
Theralase Technologies Median PS Value Historical Data
* Premium members only.
The historical data trend for Theralase Technologies's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:TLT vs ABT, SYK, MDT: Median PS Value Comparison
For the Medical Devices subindustry, Theralase Technologies's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 37.5.
Theralase Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TSXV:TLT) has a Median PS Value of C$0.15 as of Jul. 06, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Theralase Technologies and its competitors. This is 92% below median its historical median of 1.92. Over the past decade, Theralase Technologies' Median PS Value has ranged from 1.13 to 5.75. According to the industry distribution chart, Theralase Technologies ranks #312 out of 337 companies in the Medical Devices & Instruments industry, placing it in the top 92.6%.
Is Theralase Technologies' Median PS Value too high?
Theralase Technologies' current Median PS Value of C$0.15 is 92% below median its 10-year median of 1.92. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 5.75. Based on the distribution chart, Theralase Technologies ranks #312 out of 337 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theralase Technologies has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Median PS Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #312 out of 337 companies for Median PS Value. This places Theralase Technologies in the lower half of its industry. The industry median Median PS Value is 0.72. Historically, Theralase Technologies' own Median PS Value has ranged from 1.13 to 5.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.72, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current Median PS Value is C$0.15, which is 92% below median its own 10-year median of 1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TSXV:TLT) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.18, compared to a current price of C$0.26 — trading 44.4% above its estimated fair value. The current Median PS Value is C$0.15, which is 92% below median its 10-year median of 1.92. Theralase Technologies' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Theralase Technologies (TSXV:TLT), the current Median PS Value is C$0.15 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TSXV:TLT) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of C$0.26 is trading 44.4% above its estimated GF Value™ of C$0.18.
GuruFocus considers Theralase Technologies to be Significantly Overvalued.
Key valuation signals for TSXV:TLT:
Median PS Value: C$0.15 (92% below median its 10-year median of 1.92)
GF Value™: C$0.18 vs. price of C$0.26 (44.4% above fair value)
No single metric tells the full story. See the TSXV:TLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
39GF Score
Get the complete analysis for TSXV:TLT
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:TLT has been successfully added to your 
